Haemophilus influenzae type b (Hib)
Each year, Haemophilus influenzae type b (Hib) kills more than 300,000 people worldwide and causes an estimated two to three million cases of Hib disease, mostly in developing countries. Hib mainly affects children under five years of age and is a significant cause of meningitis (inflammation of the covering of the brain) and bacterial pneumonia in children. Hib can be treated with antibiotics, and conjugate Hib vaccines provide more than 95 percent protection in infants receiving the complete series of pediatric vaccination.
Hib resources on the Vaccine Resource Library were mainly gathered during PATH’s Hib project, which conducted activities in Senegal from 2005 to 2009. For additional resources, visit the Hib page on the World Health Organization website.
More about Hib | View resources on Hib
Key resources
Economic Evaluation of Delivering Haemophilus influenzae type b Vaccine in Routine Immunization Services in Kenya (2007)
A study that examines the incremental costs per case, death, and DALY, averted by delivering Hib vaccine in routine infant immunization services.
Haemophilus influenzae type b (Hib) in Central Asia (2008)
A fact sheet on Hib disease burden and the use of vaccines in Central Asia.
Progress Toward Introduction of Haemophilus influenzae type b Vaccine in Low-Income Countries—Worldwide, 2004-2007 (2008)
A report that discusses the increased use of the Hib vaccine.
Featured PATH resources
Immunizing Children Against Haemophilus influenzae type b (2006)
A training resource that provides key technical content—including sections on using monovalent, quadrivalent, or pentavalent Hib vaccine formulations—and quizzes, role plays, and creative ideas for trainers.
Page last updated: October 2011.
